Breaking down the evidence for bevacizumab in ovarian cancer Journal Article
| Authors: | Shu, C. A.; Konner, J. A. |
| Article Title: | Breaking down the evidence for bevacizumab in ovarian cancer |
| Abstract: | In1971, JudahFolkmanprophesizedthatantivascular therapies could be used to fight cancer [1]. Since the 1990s, vascular endothelial growth factor (VEGF) has been recognized as a critical element in tumorangiogenesis and as an adverse factor in ovarian cancer (OC) [2]. It has now been 10 years since the U.S. Food and Drug Administration (FDA) initially approved bevacizumab (bev), the anti-VEGF monoclonal antibody that became one of the top-selling cancer drugs in the world. Its approved indications include colorectal, lung, kidney, cervix, and (previously) breast cancers, and it has been used widely as a standard therapy forOCfor more than 5 years. Bev is licensed by the European Medicines Agency for use in first-line, first platinum-sensitive recurrence, and platinum-resistant OC. Bev was recently FDA approved for use in combination with singleagent chemotherapy for platinum-resistant disease; however, its optimal role in this cancer remains unclear. |
| Keywords: | vasculotropin; treatment response; bevacizumab; doxorubicin; drug efficacy; hypertension; gemcitabine; paclitaxel; topotecan; follow up; colorectal cancer; carboplatin; progression free survival; quality of life; multiple cycle treatment; ovary cancer; breast cancer; bleeding; lung cancer; editorial; cyclophosphamide; angiogenesis; risk factor; uterine cervix cancer; aflibercept; cediranib; pazopanib; headache; kidney cancer; digestive system perforation; proteinuria; olaparib; nose obstruction; venous thromboembolism; central nervous system disease; phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); arterial thromboembolism; human; priority journal |
| Journal Title: | The Oncologist |
| Volume: | 20 |
| Issue: | 2 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-02-01 |
| Start Page: | 91 |
| End Page: | 93 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2014-0302 |
| PROVIDER: | scopus |
| PMCID: | PMC4319628 |
| PUBMED: | 25601962 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work